SV Health Investors

SV Health Investors 在 2 个国家有直接业务。

查看带有其 28 名主要高管的组织结构图

SV Health Investors 搜索最多的简介

• Eugene Hill, Chairman of the Board
• Brent Faduski, Chief Financial Officer, Chief Compliance Officer a...
• Greg Madden, Managing Partner, Medical Devices and Healthcare

创建提醒
跟踪 SV Health Investors 的高管变动

SV Health Investors 拥有 1,533 家竞争者，其中包括 BlackRock (美国(美洲))、Vanguard (美国(美洲)) 和 Blackstone Group (美国(美洲))。

Popular M&A news in 基金

• Cansortium 已收购 RIV Capital (公布2024十二月20号).
• RIV Capital and Cansortium have announced they will merge  (公布2024十月14号)..
• Janus Henderson Group 已收购 Victory Park Capital (公布2024十月7号).

基金 行业的其他推荐联系人

• Valor Equity Partners 企业 Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer
• Vanguard 企业 Salim Ramji - Chief Executive Officer and Director
• General Catalyst Partners 企业 Hemant Taneja - Chief Executive Officer and Managing Director

了解更多有关基金行业的信息 >

SV Health Investors 的最新新闻稿

• Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform - SV Health Investors
• 2024 SV Therapeutics Impact & ESG Report - SV Health Investors
• Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors - SV Health Investors
• Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 - SV Health Investors
• Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas - SV Health Investors
• SV is hiring: Executive Assistant - SV Health Investors
• Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases - SV Health Investors
• Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System - SV Health Investors
• Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® - SV Health Investors
• LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease - SV Health Investors
• View more press releases Close

关于 SV Health Investors 的社交媒体

• SV Health Investors 在 维基百科、谷歌新闻 和 雅虎财经
• SV Health Investors 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Eugene Hill

致电SV Health Investors，电话：+44 207...

查看组织结构图

Register to receive your alert

报告错误